OXFO is revolutionizing long-term oxygen therapy (LTOT) by directly addressing the critical shortcomings of current portable oxygen devices. Traditional systems typically provide o
Investment Pitch Document
1. Introduction
OXFO is revolutionizing long-term oxygen therapy (LTOT) by directly addressing the critical shortcomings of current portable oxygen devices. Traditional systems typically provide only about 70-80% of patients' oxygen needs, leaving a significant 20-30% gap underserved globally. In contrast, OXFO's patented technology is engineered to deliver a complete 100% LTOT solution. This comprehensive approach ensures precise, real-time oxygen delivery, enhances patient mobility, reduces oxygen waste, and bolsters respiratory function. Our mission is to transform the lives of millions of oxygen-dependent patients worldwide by offering an innovative, data-driven, and patient-centric oxygen therapy solution.
2. The Problem: Challenges in Current Oxygen Therapy
Inflexible Delivery Models
Fixed Continuous Flow: Traditional oxygen systems operate continuously, providing the same rate of oxygen regardless of whether a patient is at rest or active. This static delivery fails to match the dynamic respiratory cycle of patients.
Clinical Implications: During physical exertion, patients may experience hypoxia—a dangerous reduction in oxygen levels—while at rest, the constant flow can lead to hyperoxia, exposing patients to risks such as oxidative stress and other complications.
Unmet Oxygen Needs
Partial Coverage: Research indicates that current portable oxygen devices cover approximately 70% of patients' needs. For the remaining 30%, especially for patients requiring more than 3 liters per minute, their needs are not met; they do not get the proper oxygen dose during activities, and the available devices force them to rely on bulky, heavy cylinders, severely limiting their independence and quality of life.
Oxygen Wastage
Inefficient Usage: Continuous flow systems deliver oxygen throughout the respiratory cycle, including during exhalation. This results in substantial wastage, leading to faster depletion of oxygen supplies, increased refill costs, and operational inefficiencies burdening patients and healthcare systems.
Lack of Real-Time Accountability
Absence of Monitoring: Many existing devices do not incorporate real-time monitoring mechanisms. Up to 50% of patients may not receive the correct prescribed dose of oxygen because the devices lack feedback systems that can adjust and verify the actual oxygen delivery.
Impact on Clinical Oversight: Without precise dosing data, healthcare providers cannot verify treatment adherence or make informed adjustments to therapy, which compromises patient safety and overall treatment efficacy.
Manual Adjustments and User Burden
Frequent Recalibrations: Patients and caregivers must often manually adjust the oxygen flow to try and match clinical prescriptions. This reactive approach is inherently imprecise and does not keep pace with rapid changes in a patient's condition, resulting in periods of inadequate oxygenation.
3. Our Solution: The OXFO Advantage
OXFO is engineered to overcome the limitations of conventional oxygen delivery systems through several innovative features:
Adaptive, On-Demand Oxygen Mixing
Decoupled Oxygen Reservoir: The heart of OXFO is a specialized reservoir that stores 100% oxygen at ambient pressure independently of the oxygen source pressure and flow set to refill the reservoir. This separation allows the device to mix oxygen with air at ambient pressure only at the moment of inhalation at a fixed ratio indecently of the respiratory rate or patient's respiratory flow.
Responsive Venturi Valve Technology: When the patient inhales, a unidirectional Venturi valve seamlessly blends pure oxygen with ambient air in precise ratios, ensuring that each breath contains the optimal therapeutic dose.
Enhanced Efficiency and Extended Cylinder Life
Reduced Oxygen Wastage: By delivering oxygen solely during the inhalation phase, OXFO minimizes wastage. This efficient use of oxygen extends the life of oxygen cylinders by up to three to four times, lowering refill frequencies and overall operational costs.
Dynamic Flow Adjustment: The system continuously adapts to the patient's breathing pattern, automatically increasing the flow during exertion and scaling back during rest periods. This dynamic regulation helps maintain proper oxygen levels and reduces the risks of both hypoxia and hyperoxia.
Real-Time Monitoring and Data Accountability
Integrated Sensor Network: OXFO features a suite of sensors that continuously monitor respiratory rate, oxygen reservoir levels, and the performance of the mixing valve. This data is used to fine-tune oxygen delivery in real-time.
Bluetooth and Cloud Connectivity: Real-time data is transmitted via Bluetooth to a cloud-based monitoring platform. This connectivity provides a transparent record of oxygen dosing, enabling healthcare providers, insurers, and regulatory bodies to verify that patients receive what is prescribed.
Clinical Data Aggregation: Historical usage data is stored and analyzed, offering clinicians insights into patient trends and enabling proactive adjustments to treatment plans.
Improved Patient Outcomes
Complete Oxygen Support: By fully meeting 100% of the LTOT requirements, OXFO addresses the unmet needs of the 30% of patients underserved by current technology. This comprehensive support enhances mobility, bolsters respiratory function, and improves quality of life.
Seamless Integration into Daily Life: The compact and lightweight design (weighing under five pounds) ensures patients can move freely without the encumbrance of traditional, bulky oxygen systems. This freedom is critical for maintaining independence and facilitating daily activities.
4. Technology Overview
Oxygen Delivery Mechanism
Decoupled Reservoir System: The system's innovative design segregates oxygen storage from the delivery point. This ensures that oxygen is only mixed with ambient air at the point of inhalation, thereby tailoring the oxygen concentration precisely to the patient's needs.
Venturi Valve Operation: The Venturi and unidirectional valves ensure that the oxygen and air mixture reaches the patient in the prescribed ratio.
Sensor-Driven Adaptability
Continuous Monitoring: Sensors constantly track key parameters such as respiratory rate, flow, oxygen concentration, tidal volume, and reservoir oxygen levels.
This real-time feedback loop enables the system to follow the performance of patients and equipment.
Connectivity and Data Analytics
Bluetooth Integration: The Bluetooth capabilities enable seamless data transmission to a secure, cloud-based platform.
Cloud-Based Analytics: Aggregated data is available to healthcare providers, allowing for remote monitoring, trend analysis, and proactive treatment adjustments. This data-driven approach supports enhanced patient management and opens opportunities for research and development.
Efficiency and Sustainability
Extended Cylinder Life: By delivering oxygen only during inhalation, the device maximizes the utilization of each oxygen cylinder, significantly extending its operational life.
Cost-Effective Operation: Reducing oxygen wastage directly translates into lower refill costs and improved overall efficiency, making the system more sustainable in the long run.
5. Our Team
OXFO's leadership comprises seasoned professionals with expertise in medicine, technology, operations, and finance. Their combined experience positions the company for rapid innovation and global market penetration.
Key Team Members
Carlos F. Bazoberry, M.D.
President & CEO, Co-Founder
Background: Harvard-trained anesthesiologist with over 30 years in clinical practice and healthcare innovation.
Achievements: Hold multiple patents in oxygen conservation and medical device technology; successfully led Helical RFA and Boston Pain Care Center ventures.
Vision: Driving OXFO to redefine portable oxygen therapy globally with cutting-edge technology and strategic market expansion.
Brent H. Young, M.D.
Vice-President, Co-Founder
Experience: Over 20 years in anesthesiology and medical device innovation; principal in several ventures and inventor of multiple patents.
Role: Key contributor to product design and technological integration, ensuring that OXFO meets the rigorous demands of modern oxygen therapy.
John A. Quelch (Advisor)
Executive Vice Chancellor at Duke Kunshan University; Emeritus Professor at Harvard Business School
Contributions: Offers strategic guidance and industry insights from top-tier academic and business institutions.
Impact: Helps bridge the gap between cutting-edge research and commercial viability, strengthening OXFO's market positioning.
Cecilia Antezana
Chief Operating Officer, Co-Founder
Expertise: Deep experience in global operations, finance, and strategic planning; instrumental in scaling OXFO's operational framework.
Achievements: Managed logistics and project execution for major international companies; ensured seamless execution of OXFO's growth strategy.
Dr. Adriana Arango, M.D.
Medical Director, Colombia
Role: Provides critical insights into the healthcare landscape in LATAM; ensures regulatory compliance and market relevance in the region.
Experience: Former director of pediatrics and postgraduate programs; has an extensive network within regional healthcare institutions.
Additional Leadership
Engineering & Operations: Jorge Cardona leads AI and digital transformation efforts, ensuring that OXFO's technology remains at the cutting edge.
Finance & Corporate Strategy: Guillermo Sierra brings over 20 years of experience in corporate finance, structuring investments across Europe and LATAM.
Design & IT: Claudio Arze oversees corporate image and IT infrastructure, merging innovative design with technical efficiency.
Customer Experience: Gustavo Bazoberry manages customer service operations, ensuring every patient receives top-tier support and care.
6. Market Opportunity
Expanding Demand in a Growing Market
Aging Population: With a global increase in the elderly population, the incidence of chronic pulmonary diseases is expected to rise dramatically. This demographic shift directly translates to increased demand for reliable, efficient oxygen therapy.
Rise in Respiratory Diseases: Environmental pollution, lifestyle factors, and the long-term effects of COVID-19 have collectively spurred a surge in respiratory conditions. These trends underscore the urgent need for advanced, adaptable oxygen delivery systems.
Shifting Healthcare Paradigms
Home-Based and Ambulatory Care: Modern healthcare models increasingly favor treatment solutions that allow patients to remain at home while receiving high-quality care. OXFO's portable design fits seamlessly into this model, offering mobility and efficient therapy.
Underserved Market Segment: While current devices adequately serve roughly 70% of patients, 20–30% remain underserved. With its adaptive technology and precise dosing capabilities, OXFO is uniquely positioned to address this gap.
Global Expansion Potential
Regulatory Approvals and Early Success: With approvals already secured in Colombia, Chile, the Dominican Republic, and Honduras—and ongoing efforts in the U.S., E.U., and Mexico—OXFO is poised for rapid global expansion.
Strategic Market Entry: Planned entry into Asian markets (beginning with Singapore in 2026) further enhances the company's revenue potential, tapping into a broader international patient base.
Market Size: The portable oxygen therapy market is estimated to be worth over $6.5 billion, with millions of patients worldwide needing improved solutions.
7. Capital Raise and Use of Proceeds
Funding Requirements
Total Capital Sought: $3 Million
Committed Capital: $1.5 Million already allocated for expansion milestones.
Achieved Milestones
Production Launch (December 2024): Successfully initiated production with the first 170 units for Colombia and Chile.
Clinical Validation: Peer-reviewed research published in the Journal of Global Health (October 2024) confirms the superior performance and efficiency of OXFO.
Regulatory Progress: Ongoing approvals in the U.S., E.U., and Mexico are set to open additional high-value markets in 2026.
Distribution Network: Over 10 distribution partners in Colombia validate early market acceptance and lay the groundwork for global expansion.
Planned Use of Funds
Regulatory Approvals: Complete necessary certifications in key markets (U.S., E.U., Mexico) to secure market entry.
Production Scaling: Expand manufacturing capacity to meet global demand, improving economies of scale and reducing unit costs.
Market Penetration and Sales: Invest in aggressive marketing, sales expansion, and establishing robust distribution channels in North America, Europe, LATAM, and Asia.
Technology Enhancements: Develop next-generation digital health integrations and expand clinical trials in collaboration with institutions such as SURA (Health Insurance) in LATAM and the University of Salamanca (Spain).
Operational Expansion: Strengthen logistics, supply chain management, and customer service frameworks to support rapid growth and ensure operational excellence.
8. Traction and Early Market Success
Initial Market Adoption
Regional Leadership: Over the past two years, OXFO has established a presence in South America, validating both the clinical efficacy of the device and its market demand.
Distributor and Partner Network: The early establishment of more than 10 distribution partnerships in Colombia demonstrates robust market acceptance and provides a springboard for international expansion.
Clinical and Regulatory Validation: Peer-reviewed research and ongoing regulatory reviews further underpin the credibility and effectiveness of the OXFO system, ensuring confidence among healthcare providers and investors alike.
Future Milestones
Regulatory Completion: Finalizing approvals in the U.S., E.U., and Mexico by spring 2026 will significantly broaden our market reach.
Production and Sales Scaling: Enhancing production capabilities and penetrating new markets will drive revenue growth and pave the way for long-term success.
Technology and Data Integration: Continued R&D investments and integration of advanced remote monitoring platforms will position OXFO as the leader in data-driven oxygen therapy.
9. Role of your Investment
Strategic Catalysis for Global Growth
Accelerating Regulatory Approvals: Your investment expedites the regulatory process in high-value markets like the U.S. and Europe. Achieving swift clearance will boost market credibility and pave the way for additional funding from institutional investors.
Expanding Production and Market Reach: With additional capital, OXFO will scale production to meet global demand while expanding its market presence across North America, Europe, LATAM, and Asia. This expansion is crucial to tapping into the $6.5 billion market and reaching millions of patients worldwide.
Enhancing Operational Efficiency and Data Transparency: The investment will also drive further technological enhancements—including advanced sensor calibration, improved cloud-based data analytics, and integration of next-generation digital health features—which will solidify OXFO's competitive edge.
Boosting Investor and Partner Confidence: A robust regulatory pathway and evident market traction, bolstered by your investment strategic backing, will enhance investor confidence. This, in turn, will facilitate additional private capital inflows and form the basis for strategic partnerships with key healthcare providers, insurers, and distribution networks.
Long-Term Value Creation: Your investment support is an injection of capital and a strategic partnership that will help accelerate commercialization, drive sustainable revenue growth, and position OXFO as a market leader in portable oxygen therapy.
10. Conclusion
OXFO's groundbreaking approach to oxygen therapy addresses critical shortcomings in current technologies—offering adaptive, on-demand oxygen delivery, real-time monitoring, and significant efficiency gains. With a highly experienced leadership team, robust market traction, and clear pathways to global expansion, OXFO represents a unique investment opportunity in a market poised for growth. The strategic partnership with your investment will catalyze our next development phase, ensuring that we deliver on our promise to improve patient outcomes and redefine the future of oxygen therapy.
We invite you to join us in this transformative journey as we set a new standard in respiratory care worldwide.
